Network officials also said voters should expect more of a Koch focus on grassroots activism throughout the 2020 election cycle.Politicsread more
In a room full of avowed capitalists, policies that sound to some like socialism are bound not to go over well.Delivering Alpharead more
GM's usage of temporary workers, potential closure of plants and health care contributions remain major sticking points, according to people familiar with the talks.Autosread more
At least in terms of monetary policy, Pence says should be taking after other regions who keep their benchmark interest rates near zero.Delivering Alpharead more
AT&T isn't focused on selling or divesting DirecTV, despite pressure from stakeholder Elliott Management, sources tell CNBC.Technologyread more
The measure to keep the government running through Nov. 21 now heads to the Senate, where McConnell has signaled he will back a temporary spending plan.Politicsread more
Amazon's purchase comes as part of its plan to convert its delivery fleet to 100% renewable energy by 2030. The e-commerce retailer already runs 40% of its fleet on renewable...Autosread more
As part of the plan, Amazon has agreed to purchase 100,000 electric delivery vans from vehicle manufacturer Rivian.Technologyread more
American Airlines struggled with flight delays and cancellations this summer, hamstrung by the grounded Boeing 737 Max and mired in a bitter labor dispute with its mechanics.Airlinesread more
Apple's iOS 13.1 will be released on Sept. 24, six days earlier than previously announced.Technologyread more
Stripe, a payments company, announced an additional $250 million funding round on Thursday, bringing its valuation to $35 billion.CNBC Disruptor 50read more
May the best drug win. That's how Merck Chief Executive Ken Frazier views the competition to treat the as many as 150 million people worldwide with hepatitis C.
The pharma giant has a combination of drugs in late-stage trials that would provide patients with hepatitis C an option that doesn't require injections of medicines, including interferon, which can cause nasty side effects.
Merck's treatment received breakthrough therapy designation from the Food and Drug Administration, which aims to speed important drugs to market. However, medicines from Gilead Sciences, Bristol-Myers Squibb, and AbbVie have the same status.
So how will Merck compete?
"I think, over time, the best drug wins," Frazier said in an interview with CNBC at Merck Research Laboratories in Boston on Tuesday. "We think our combination's going to be a very formidable competitor. It's an all-oral, once-a-day pill, it doesn't have interferon, it works across many genotypes and it can be used for patients who have comorbidities."
Frazier didn't say that the way to compete is on price—a particularly important point now as Gilead's drug, Sovaldi, has become a lightning rod for criticism over drug pricing.
Sovaldi, which was approved in December 2013, costs $84,000 for a 12-week course of treatment, a price that's drawn scrutiny from health insurers, patient advocacy groups and Congress. The drug drew $2.27 billion in first-quarter revenue.
Frazier reiterated a stance Gilead has taken, noting that use of effective drugs for hepatitis C could prevent greater costs associated with the disease later in its course. Hepatitis C can lay dormant for years before showing symptoms. It also comes in multiple forms, called genotypes, and often patients have other maladies, known as comorbidities.
More than 75 percent of adults infected are baby boomers, and most don't know they're infected, according to the Centers for Disease Control and Prevention. Over time, the virus can cause liver damage, scarring and cancer, making it the leading cause of liver transplants.
Read MoreCan Gilead's Sovaldi rescue biotech?
"People don't realize that the real impact to society of hepatitis C is yet to be felt, because the wave of cirrhotic patients is about eight years from now," Frazier said. "There's a lot that we need to do as a society to prevent all the costs of liver transplants and the like."
At the moment, Gilead's Sovaldi is an early leader on the market, while drugs from Merck, AbbVie and Bristol-Myers are still in testing. Johnson & Johnson also has a new hepatitis C drug on the market, called Olysio.
The World Health Organization is among critics of the new drugs' pricing, saying that while the production cost of the medicines is low, "the initial prices set by companies are very high and likely to make access to these drugs difficult even in high-income countries."
—By CNBC's Meg Tirrell.